Literature DB >> 32149190

The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace.

Kathryn A Phillips1,2,3, Michael P Douglas1.   

Abstract

The market for next-generation sequencing technologies (NGS) has grown dramatically. Health care decision-makers need empirical evidence on market growth and future trends in order to develop appropriate strategies and policies, but little has been published about the nature and size of these trends. We provide a snapshot of market trends through 2020. We found rapid growth of clinical NGS - the global clinical NGS services market was $2.2 billion in 2015 and is forecast to reach $7.7 billion by 2020. The reproductive health NGS test market is the largest market followed by the oncology NGS test market. The largest market is for tests that sequence >50 genes but not the entire exome or genome. Markets are growing rapidly in countries outside of the US. Despite rapid NGS test growth, there are a number of key issues that will need to be addressed to facilitate appropriate future growth.

Entities:  

Year:  2018        PMID: 32149190      PMCID: PMC7059995     

Source DB:  PubMed          Journal:  J Precis Med


  8 in total

1.  Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.

Authors:  Julia R Trosman; Christine B Weldon; Michael P Douglas; Allison W Kurian; R Kate Kelley; Patricia A Deverka; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2017-02-10       Impact factor: 11.908

2.  Payer coverage policies for multigene tests.

Authors:  Kathryn A Phillips; Patricia A Deverka; Julia R Trosman; Michael P Douglas; James D Chambers; Christine B Weldon; Andrew P Dervan
Journal:  Nat Biotechnol       Date:  2017-07-12       Impact factor: 54.908

3.  Insurance coverage for genomic tests.

Authors:  Kathryn A Phillips; Julia R Trosman; Patricia A Deverka; Bruce Quinn; Sean Tunis; Peter J Neumann; James D Chambers; Louis P Garrison; Michael P Douglas; Christine B Weldon
Journal:  Science       Date:  2018-04-19       Impact factor: 47.728

4.  EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.

Authors:  James D Chambers; Cayla J Saret; Jordan E Anderson; Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Int J Technol Assess Health Care       Date:  2017-10-25       Impact factor: 2.188

5.  Availability and payer coverage of BRCA1/2 tests and gene panels.

Authors:  Elizabeth Clain; Julia R Trosman; Michael P Douglas; Christine B Weldon; Kathryn A Phillips
Journal:  Nat Biotechnol       Date:  2015-09       Impact factor: 54.908

6.  Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

Authors:  Kathryn A Phillips
Journal:  JAMA       Date:  2018-06-19       Impact factor: 56.272

7.  Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening.

Authors:  Andrew P Dervan; Patricia A Deverka; Julia R Trosman; Christine B Weldon; Michael P Douglas; Kathryn A Phillips
Journal:  Genet Med       Date:  2016-09-22       Impact factor: 8.822

8.  Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited.

Authors:  Michael P Douglas; Stephanie L Parker; Julia R Trosman; Anne M Slavotinek; Kathryn A Phillips
Journal:  Genet Med       Date:  2018-07-12       Impact factor: 8.822

  8 in total
  5 in total

1.  Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation.

Authors:  Kathryn A Phillips; Michael P Douglas; Deborah A Marshall
Journal:  JAMA       Date:  2020-11-24       Impact factor: 56.272

2.  The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care.

Authors:  Salma Shickh; Sara A Rafferty; Marc Clausen; Rita Kodida; Chloe Mighton; Seema Panchal; Justin Lorentz; Thomas Ward; Nicholas Watkins; Christine Elser; Andrea Eisen; June C Carroll; Emily Glogowski; Kasmintan A Schrader; Jordan Lerner-Ellis; Raymond H Kim; David Chitayat; Cheryl Shuman; Yvonne Bombard
Journal:  Genet Med       Date:  2021-03-02       Impact factor: 8.864

Review 3.  Availability and funding of clinical genomic sequencing globally.

Authors:  Kathryn A Phillips; Michael P Douglas; Sarah Wordsworth; James Buchanan; Deborah A Marshall
Journal:  BMJ Glob Health       Date:  2021-02

4.  Opportunity of Next-Generation Sequencing-Based Short Tandem Repeat System for Tumor Source Identification.

Authors:  Anqi Chen; Lei Xiong; Yiling Qu; Shihan Xi; Ruiyang Tao; Chengtao Li; Suhua Zhang
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

5.  seGMM: A New Tool for Gender Determination From Massively Parallel Sequencing Data.

Authors:  Sihan Liu; Yuanyuan Zeng; Chao Wang; Qian Zhang; Meilin Chen; Xiaolu Wang; Lanchen Wang; Yu Lu; Hui Guo; Fengxiao Bu
Journal:  Front Genet       Date:  2022-03-03       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.